Subscribe to Newsletter
Please enter your name and email address if you would like to subscribe to the monthly Thrombosis Adviser Newsletter.
Intermittent pneumatic compression with inflatable sleeves that fit over the legs reduced the occurrence of deep vein thrombosis (DVT) in immobile patients who had had a recent stroke in the CLOTS 3 study.
Using beta-blockers after heart surgery reduces the risk of dangerous abnormal heart rhythms, according to a analysis. One complication after heart surgery is atrial fibrillation (AF), where the two upper chambers of the heart quiver, rather than beating effectively.
Rivaroxaban […] has been approved in Europe for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) following an acute coronary syndrome (ACS). The drug was approved at a dose of 2.5 mg twice-daily and should be used in combination with standard antiplatelet therapy. Rivaroxaban is now the only oral anticoagulant to receive an ACS indication.
These contemporary observational worldwide data on non-valvular atrial fibrillation, collected at the end of the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke.
Systematic screening in GP practices for atrial fibrillation could identify more people with the disease than routine practice, according to a gold-standard review.
Low-dose aspirin is widely used as prevention for myocardial infarction and other cardiovascular diseases, but there is evidence that concurrent use of NSAIDs may inhibit the antiplatelet effect of aspirin.
Should recurrences after a failed ablation in patients with paroxysmal atrial fibrillation (AF) be treated with antiarrhythmic drugs (AAD) or with a repeat pulmonary vein isolation (PVI) procedure? More likely second time's the charm, suggests a randomized trial showing that repeat ablation is much more likely than AAD to get rid of a recurrence.
Although young patients with acute coronary syndromes typically carry traditional cardiovascular risk factors, some of them show no evidence of underlying coronary artery disease, researchers found.
Adopting seven simple lifestyle steps could help reduce your risk of these potentially deadly blood clots, according to a new study.
A practical guide on the use of the new oral anticoagulants (NOACs) has been produced by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). A guide was needed to summarise existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make distinctions between the different drugs.
In an effort to better the lives of patients in the first year after an initial acute coronary syndrome (ACS) event, the American College of Physicians (ACP) has released a pair of evidence-based interventions and two videos for clinicians and patients to heed.
Add-on anticoagulant therapy after stent deployment for acute coronary syndromes (ACS) significantly reduced the risk of stent thrombosis and mortality in patients already receiving dual antiplatelet therapy, according to a new analysis of a large randomized trial.
Left anterior fascicular block (LAFB), an electrocardiographic abnormality previously considered benign, is associated with a significantly increased long-term risk of atrial fibrillation (AF), congestive heart failure, and death, according to the results of a new analysis published April 16, 2013 in the Journal of the American Medical Association.
Interventions aim to improve health outcomes in patients after blood flow to heart muscle is suddenly blocked.
Glucocorticoids may increase the risk of venous thromboembolism (VTE), irrespective of how they are administered, suggests a large, population-based case–control study from Denmark.
The three newest anticoagulants -- dabigatran […], apixaban […], and rivaroxaban […] -- are cost-effective relative to warfarin for preventing stroke in patients with nonvalvular atrial fibrillation, researchers found.
Everolimus-eluting stents are associated with lower rates of stent thrombosis compared with paclitaxel-eluting stents in those with diabetes, but after adjustment, the composite rate of target lesion revascularization major adverse events was similar between stent types at 1 year, study results have concluded.
Women who have suffered a still birth or have medical conditions including varicose veins, inflammatory bowel disease (IBD) or heart disease are at greater risk of developing dangerous blood clots after giving birth, a study has revealed.
The Committee for Medicinal Products for Human Use has adopted a positive opinion for expanding the indication of rivaroxaban to include patients with ACS, according to a press release issued by the agency.
New Thrombosis publications available for February 2013.
Higher levels of pregnancy-associated plasma protein A (PAPP-A) were associated with an increased risk of cardiovascular events in people with cardiac chest pain that developed as a result of heart disease/coronary artery disease, according to a study published in CMAJ.
The use of vena cava filters in patients with acute venous thromboembolism varied widely in California hospitals, not only according to clinical indications but also after adjusting for important confounders such as the hospital size, rural location and type of hospital.
A significant number of U.S. patients with irregular heart rhythms do not receive adequate therapy, according to a new study of treatment practices for atrial fibrillation.
The risk of cardiac death, MI, or stroke was the same whether patients stayed on aspirin plus clopidogrel for at least 36 months or shifted to aspirin alone after 12 months, Cheol Whan Lee, MD, of Asan Medical Center in Seoul, South Korea, and colleagues found.
More than 900,000 Americans each year have a deep vein thrombosis or pulmonary embolism episode which can result in damage to their lungs or other organs and can be fatal. The CHEST Foundation, as part of its OneBreath Initiative, announced the launch of kNOw DVT, a month-long awareness effort that features a series of online resources developed by the American College of Chest Physicians to help educate consumers affected by DVT or who are looking to learn more.
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine.
After reports of having met the primary endpoints in the ATLAS-ACS TIMI-51 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
Statin-naïve patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) scheduled for early invasive procedures who receive high-dose rosuvastatin on admission have a significantly lower incidence of contrast-induced acute kidney injury (CI-AKI) and a reduction in 30-day adverse clinical events, according to results of the PRACTO-ACS study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
Janssen Research & Development, LLC (Janssen) today announced the launch of EXPLORER, a comprehensive, global research program for […] (rivaroxaban), an oral anticoagulant. The program includes studies […] for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease.
Patients with atrial fibrillation are at an increased risk of ischemic stroke. In this high-risk population, vitamin K antagonists such as warfarin have been shown to be highly effective in preventing this event. However, the afflicted often receive multiple antithrombotic drugs such as warfarin in combination with aspirin and clopidogrel to manage their associated cardiovascular conditions.
New Thrombosis publications available for December 2012.
Atrial fibrillation is the most common type of abnormal heart rhythm, affecting 2.5 million Americans. If left undetected or untreated, atrial fibrillation can lead to stroke. Determining who is at increased risk for atrial fibrillation has been difficult, especially among individuals without established heart disease.
Publication of the WOEST trial results reaffirm the study's major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention (PCI) who are receiving oral anticoagulant therapy.
Atrial fibrillation (AF) may play an intermediary role in the relationship between obstructive sleep apnea (OSA) and stroke, research findings suggest.
The CHADS-based risk scores can predict long-term vascular outcomes and mortality in patients with stroke who do not have atrial fibrillation (AF), research suggests.
Patients with atrial fibrillation who present to the emergency department for other conditions have a higher risk of death than patients who present with atrial fibrillation as their primary diagnosis, according to the results of a new analysis.
Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to research presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium […].
Dabigatran-treated patients had a recurrent VTE rate of 1.8% versus 1.3% with warfarin in a trial involving 2,856 patients with a history of VTE.
Switching high-risk patients to clopidogrel […] can help counteract the low platelet reactivity common with prasugrel […], but doing so has risks of its own, a first-of-its-kind study found.
Prolonged ambulatory cardiac monitoring after a cryptogenic ischemic stroke or transient ischemic attack appears to be a more effective method for detecting occult atrial fibrillation than standard methods.
First presented at the American College of Cardiology (ACC) 2011 Scientific Sessions by lead investigator Dr Alexander Cohen (King's College, London, UK) […], the study shows that rivaroxaban is noninferior to standard 10-day treatment with enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism (VTE) at day 10 and is superior to enoxaparin for the prevention of the same clinical events at day 35.
The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical management of a disease that is a leading cause of morbidity and mortality.
The development of new antithrombotic agents for the treatment of ACS and other cardiovascular diseases is a rapidly evolving and increasingly complex field. Optimizing the prevention of ischaemic events and simultaneously minimizing bleeding risks are central to improving patient outcomes.
ABO blood type had an additive effect on the risk of venous thromboembolism when combined with factor V Leiden R506Q and prothrombin G20210A mutations; blood type was the most important risk factor for venous thromboembolism in the general population.
New guidelines on stroke care stress that getting clot-busting drugs and other treatments within one hour of arriving in the emergency room is crucial to minimizing brain damage and speeding recovery.
ACS patients treated with prasugrel experience fewer ischemic complications but more bleeding than those receiving clopidogrel, and individualized thienopyridine selection could maximize the benefits and safety of these drugs, results from a recent study suggest.
Prasugrel and ticagrelor showed several differences on their pharmacological profiles and their disparity may reflect their different reversibility and/or pharmacokinetic profiles.
Serial compression ultrasonography with iliac vein visualization can reliably exclude deep vein thrombosis (DVT) in symptomatic pregnant women, according to results from an 8-year prospective cohort study published in the Canadian Medical Association Journal.
For patients with ST-segment elevation myocardial infarction, high-sensitivity C-reactive protein measurements at presentation predict subsequent nonfatal myocardial infarction and cardiac death; and for patients with acute coronary syndromes, fetuin-A and C-reactive protein have prognostic value, according to two studies published in the Jan. 1 issue of The American Journal of Cardiology.
Many people who suffer from chronic kidney disease progressively lose their kidney function over time and eventually develop a condition called end-stage renal disease - the complete failure of the kidneys - placing them in need of lifelong dialysis or a kidney transplant.
Pregnant women have an increased risk of venous thromboembolism and pulmonary embolism after in vitro fertilization (IVF), especially during the first trimester, according to a study published online Jan. 15 in BMJ.